Targeting fibrosis: Mechanisms and clinical trials

M Zhao, L Wang, M Wang, S Zhou, Y Lu… - Signal transduction and …, 2022 - nature.com
Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

F Wu, J Yang, J Liu, Y Wang, J Mu, Q Zeng… - … and Targeted Therapy, 2021 - nature.com
To flourish, cancers greatly depend on their surrounding tumor microenvironment (TME),
and cancer-associated fibroblasts (CAFs) in TME are critical for cancer occurrence and …

The JAK/STAT signaling pathway: from bench to clinic

X Hu, J Li, M Fu, X Zhao, W Wang - Signal transduction and targeted …, 2021 - nature.com
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Targeting cancer stem cell pathways for cancer therapy

L Yang, P Shi, G Zhao, J Xu, W Peng, J Zhang… - Signal transduction and …, 2020 - nature.com
Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

Strategies to therapeutically modulate cytokine action

WJ Leonard, JX Lin - Nature Reviews Drug Discovery, 2023 - nature.com
Cytokines are secreted or membrane-presented molecules that mediate broad cellular
functions, including development, differentiation, growth and survival. Accordingly, the …

Mechanisms and consequences of Jak–STAT signaling in the immune system

AV Villarino, Y Kanno, JJ O'Shea - Nature immunology, 2017 - nature.com
Abstract Kinases of the Jak ('Janus kinase') family and transcription factors (TFs) of the STAT
('signal transducer and activator of transcription') family constitute a rapid membrane-to …

JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects

S Banerjee, A Biehl, M Gadina, S Hasni, DM Schwartz - Drugs, 2017 - Springer
The Janus kinase/signal transduction and activator of transcription (JAK–STAT) signaling
pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases …

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

PG Traves, B Murray, F Campigotto, R Galien… - Annals of the …, 2021 - ard.bmj.com
Objective Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with
variable reported rates of adverse events, potentially related to differential JAK family …

The emerging safety profile of JAK inhibitors in rheumatic disease

KL Winthrop - Nature Reviews Rheumatology, 2017 - nature.com
Tofacitinib is the first Janus kinase (JAK) inhibitor commercially approved for the treatment of
rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently …

Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: functions and therapeutic implication

CY Loh, A Arya, AF Naema, WF Wong, G Sethi… - Frontiers in …, 2019 - frontiersin.org
Signal Transducer and Activator of Transcription (STAT) pathway is connected upstream
with Janus kinases (JAK) family protein and capable of integrating inputs from different …